Phenotype-specific therapy selection may include NLRP3 inhibitors for frequent exacerbators, AIM2 inhibitors for emphysema-dominant patients, and IL-33 pathway modulators for chronic bronchitis phenotypes. This evidence concerns the gene AIM2 and pulmonary emphysema.